Literature DB >> 28743702

Progressive Dispersion of Azole Resistance in Aspergillus fumigatus: Fatal Invasive Aspergillosis in a Patient with Acute Myeloid Leukemia Infected with an A. fumigatus Strain with a cyp51A TR46 Y121F M172I T289A Allele.

Susann Rößler1, Oliver Bader2, Friedrich Stölzel3, Ulrich Sommer4, Birgit Spiess5, Stephan Geibel2, Dieter Buchheidt5, Uwe Groß2, Gustavo Baretton4, Enno Jacobs6, Luis Ostrosky-Zeichner7.   

Abstract

Patients with hematologic malignancies as well as allogeneic hematopoietic stem cell transplantation (HSCT) patients are at high risk for invasive aspergillosis. Here, we report a culture- and autopsy-proven fatal invasive aspergillosis in an allogeneic HSTC patient which he developed despite posaconazole prophylaxis. The agent was determined to be an azole-resistant Aspergillus fumigatus strain bearing the cyp51A mutation combination TR46 Y121F M172I T289A. At increasing frequency, the azole resistance of A. fumigatus is being reported globally, limiting treatment options and complicating regimens.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Aspergillus fumigatus; azole resistance; breakthrough aspergillosis; cyp51A mutation; hematopoietic stem cell transplantation; invasive aspergillosis

Mesh：

Substances：

Year:  2017        PMID： 28743702      PMCID： PMC5527573          DOI： 10.1128/AAC.00270-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  32 in total

Review 1.  Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis.

Authors:  Monique A S H Mennink-Kersten; J Peter Donnelly; Paul E Verweij
Journal:  Lancet Infect Dis       Date:  2004-06       Impact factor: 25.071

2.  Aspergillus galactomannan index: a surrogate end point to assess outcome of therapy?

Authors:  Kieren A Marr
Journal:  Clin Infect Dis       Date:  2008-05-01       Impact factor: 9.079

3.  First determination of azole resistance in Aspergillus fumigatus strains carrying the TR34/L98H mutations in Turkey.

Authors:  Gülşah Ece Özmerdiven; Seçil Ak; Beyza Ener; Harun Ağca; Burcu Dalyan Cilo; Berrin Tunca; Halis Akalın
Journal:  J Infect Chemother       Date:  2015-05-14       Impact factor: 2.211

4.  Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany.

Authors:  J Steinmann; A Hamprecht; M J G T Vehreschild; O A Cornely; D Buchheidt; B Spiess; M Koldehoff; J Buer; J F Meis; P-M Rath
Journal:  J Antimicrob Chemother       Date:  2015-01-27       Impact factor: 5.790

5.  Early intervention with allogeneic hematopoietic cell transplantation during chemotherapy-induced aplasia in patients with high-risk acute myeloid leukemia.

Authors:  F Stölzel; U Platzbecker; B Mohr; C Röllig; J M Middeke; C Thiede; M Füssel; M Hänel; M Schaich; G Ehninger; J Schetelig; M Bornhäuser
Journal:  Leukemia       Date:  2013-05-07       Impact factor: 11.528

6.  Development of novel PCR assays to detect azole resistance-mediating mutations of the Aspergillus fumigatus cyp51A gene in primary clinical samples from neutropenic patients.

Authors:  Birgit Spiess; Wolfgang Seifarth; Natalia Merker; Susan J Howard; Mark Reinwald; Anne Dietz; Wolf-Karsten Hofmann; Dieter Buchheidt
Journal:  Antimicrob Agents Chemother       Date:  2012-04-23       Impact factor: 5.191

7.  Multicenter evaluation of an enzyme immunoassay (Platelia Aspergillus) for the detection of Aspergillus antigen in serum.

Authors:  Gianluigi Lombardi; Claudio Farina; Stefano Andreoni; Domenico D'Antonio; Elisabetta Faggi; Esther Manso; Aldo Mazzoni
Journal:  Mycopathologia       Date:  2002       Impact factor: 2.574

8.  Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles.

Authors:  Jan W M van der Linden; Simone M T Camps; Greetje A Kampinga; Jan P A Arends; Yvette J Debets-Ossenkopp; Pieter J A Haas; Bart J A Rijnders; Ed J Kuijper; Frank H van Tiel; János Varga; Anna Karawajczyk; J Zoll; Willem J G Melchers; Paul E Verweij
Journal:  Clin Infect Dis       Date:  2013-05-10       Impact factor: 9.079

9.  Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

Authors:  Sabine Mousset; Dieter Buchheidt; Werner Heinz; Markus Ruhnke; Oliver A Cornely; Gerlinde Egerer; William Krüger; Hartmut Link; Silke Neumann; Helmut Ostermann; Jens Panse; Olaf Penack; Christina Rieger; Martin Schmidt-Hieber; Gerda Silling; Thomas Südhoff; Andrew J Ullmann; Hans-Heinrich Wolf; Georg Maschmeyer; Angelika Böhme
Journal:  Ann Hematol       Date:  2013-09-12       Impact factor: 3.673

10.  Incidence of Cyp51 A key mutations in Aspergillus fumigatus-a study on primary clinical samples of immunocompromised patients in the period of 1995-2013.

Authors:  Birgit Spiess; Patricia Postina; Mark Reinwald; Oliver A Cornely; Axel Hamprecht; Martin Hoenigl; Cornelia Lass-Flörl; Peter-Michael Rath; Jörg Steinmann; Thomas Miethke; Melchior Lauten; Silke Will; Natalia Merker; Wolf-Karsten Hofmann; Dieter Buchheidt
Journal:  PLoS One       Date:  2014-07-29       Impact factor: 3.240
View more
  4 in total

Review 1.  Molecular Tools for the Detection and Deduction of Azole Antifungal Drug Resistance Phenotypes in Aspergillus Species.

Authors:  Anna Dudakova; Birgit Spiess; Marut Tangwattanachuleeporn; Christoph Sasse; Dieter Buchheidt; Michael Weig; Uwe Groß; Oliver Bader
Journal:  Clin Microbiol Rev       Date:  2017-10       Impact factor: 26.132

2.  New Antifungal Susceptibility Test Based on Chitin Detection by Image Cytometry.

Authors:  Yan Wang; Arisandy N Andriampamonjy; Sebastien Bailly; Cécile Garnaud; Danièle Maubon; Muriel Cornet; Delphine Aldebert
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

3.  Comparison of Two Molecular Assays for Detection and Characterization of Aspergillus fumigatus Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients.

Authors:  Patricia Postina; Julian Skladny; Tobias Boch; Oliver A Cornely; Axel Hamprecht; Peter-Michael Rath; Jörg Steinmann; Oliver Bader; Thomas Miethke; Anne Dietz; Natalia Merker; Wolf-Karsten Hofmann; Dieter Buchheidt; Birgit Spiess
Journal:  Front Microbiol       Date:  2018-03-27       Impact factor: 5.640

Review 4.  Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications.

Authors:  Thomas R Rogers; Paul E Verweij; Mariana Castanheira; Eric Dannaoui; P Lewis White; Maiken Cavling Arendrup
Journal:  J Antimicrob Chemother       Date:  2022-07-28       Impact factor: 5.758
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.